Skip to content
Open menu

Prostate cancer pharmacotherapy

Drug therapy is used for advanced and high-risk prostate cancer. At Docrates Cancer Center, we take advantage of the latest treatments and make an individual treatment plan for each of our patients.

New prostate cancer drugs are effective and well tolerated

Pharmacotherapy is most commonly administered for metastasised prostate cancer, but it’s also used as an additional therapy for localised high risk cancer. Many new, effective drugs intended for the treatment of metastasised cancer have entered the market – they are all available at Docrates.

The new drugs are also often suitable for the elderly, patients with multiple illnesses, and combination therapy. The new prostate cancer drugs are often both more effective and better tolerated than previous drugs, and may even work after prior medication has lost its effectiveness. The new medicines can be used to alleviate symptoms, slow down disease progression in the bones in particular, and increase lifetime – the aim is for the patient to be able to continue leading as normal a life as possible.

There are three main types of new prostate cancer drugs:

1) Targeted hormonal therapy in the form of pills (secondary hormonal therapy)

  • For example, abiraterone and enzalutamide

2) Cytostatic drugs

  • For example, intravenously administered cabazitaxel

3) Radionuclide therapies intended for the treatment of metastases

  • Intravenously administered Radium‑223 targets bone metastases
  • Intravenously administered radioactive drug Lu-PSMA  effectively treats metastases both in soft tissues and in the bone

Read more

Verification of identification

Please be prepared to present an identity document when you register at the reception.

Read more

Investments in diagnostics, cancer treatment and services – Docrates Cancer Center published its 2023 annual review

In 2023, Docrates Cancer Center promoted its strategy by investing in larger facilities, developing services related to the early detection...

Customer infoletter 21, May 2024

Docrates Cancer Center becomes part of Mehiläinen through an acquisition signed on 16 May 2024. The transaction requires the approval...

Docrates Cancer Center becomes part of Mehiläinen

Docrates Cancer Center, which specialises in the diagnostics, treatment and monitoring of cancer, becomes part of Mehiläinen through an acquisition...

Why come to Docrates Cancer Center?

  • Top cancer experts and effective treatments without delay.
  • Individual care. You have your own care team - your doctor and your nurse.
  • Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
  • Experience in treating international patients from over 60 countries. Multilingual personnel.
+358 10 773 2010

Contact us!

Mon-Thu 8:00-18:00, Fri 8:00-16:00